Clinical Trials

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT06780137 2026-03-16

MK-6070-002

262 enrolled

Small Cell Lung Carcinoma

NCT06287775 2026-03-12

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

45 enrolled

Phase 1/2 Active not recruiting

Lung Neoplasms

NCT02734004 2026-01-29

MEDIOLA

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT07174583 2026-01-23

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Phase 1/2 Active not recruiting

208 enrolled

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT04748419 2026-01-22

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

6 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

40 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05932199 2025-09-25

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Other solid neoplasmThoracic

52 enrolled

Mesothelioma

NCT03148327 2025-07-15

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

Phase 1/2 Active not recruiting

18 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03212469 2025-05-08

ABIMMUNE

GastrointestinalHead & NeckThoracic

54 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Lung Neoplasms

NCT05451173 2023-10-03

Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

Phase 1/2 Unknown

83 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04646837 2023-03-29

Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

Phase 1/2 Unknown

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02898116 2022-10-10

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

2 enrolled 8 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05267392 2022-03-04

IDEAR

Phase 1/2 Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02318277 2022-01-13

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

176 enrolled 25 charts

Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

NCT02805660 2021-04-06

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Phase 1/2 Terminated

83 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02403271 2019-01-03

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors